Breaking news from me this morning: Recursion Pharmaceuticals' Chris Gibson, who promised 100 drugs in 10 years in the early days of the tech-powered company, is stepping down as CEO.
https://www.statnews.com/2025/11/05/recursion-ceo-chris-gibson-out-najat-khan-new-head/
#health #healthcare #medicine #biotech #techbio #pharma #ai #drugdiscovery
TechBio is leveraging AI, genomics, and immunotherapy to transform cancer treatment, aiming to make it more personalized and accessible.TechBio is at the forefront of revolutionizing cancer treatment through cutting-edge technologies like AI, genomics, and immunotherapy. #AI #cancertreatment #genomics #immunotherapy #TechBio
https://redrobot.online/2025/01/techbio-innovations-pave-the-way-for-personalized-cancer-care/
At Spring Science, we're using specialized AI to revolutionize drug discovery—accelerating the development of life-changing treatments by compressing years of progress into a fraction of the time.
Our AI platform analyzes vast biological data, uncovering insights that could take traditional methods decades to find. The future of medicine is here, driven by AI. Stay tuned! #AI #DrugDiscovery #TechBio
🧑💻👩💻 👩🔬 👨🔬 As a #techbio company, our culture is centered on our scientific and tech roots. This week is one of our semi-annual favorites - our own Spring #Hackathon!
Our team takes the week to highly focus on projects that span everything from our customer's biggest requests to our own new ideas. The Spring Hackathon is perfect platform for our team to tackle pressing challenges and work on 🚀 #moonshot🚀 projects that will shape the future of #AI, #drugdiscovery and (🧵 )
Exciting new collaboration that brings together clinical expertise in prostate cancer (second leading cause of cancer death for men) with the latest advances in instruments and AI technologies for atomic resolution of molecular structure. From our portfolio company Peptone based in Switzerland and the UK.
The power comes from the ability to specify a one dimensional representation, the primary sequence, that will self-assemble into 3 dimensional structures. And the relatively simpler rules that govern this, due to the smaller diversity of charges and shapes of nucleotides (versus the larger diversity of amino acid residues) means it is more feasible to develop engineering rules for 3D designs.
DNA sequencing is the “Moore’s Law” for biotech: transcriptomics, proteomics, spatial genomics, etc. leverage cheap/powerful sequencing to advance exponentially.
And now, the "inverse" of DNA sequencing is rising: DNA molecular engineering that use nucleic acids as programmable lego blocks for smart materials, such as DNA origami, strand-displacement, aptamers & molecular switches, etc.